Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage.
Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
New England Journal of Medicine publishes results from Phase 3 induction and maintenance programs evaluating upadacitinib (RINVOQ ®) in Crohn & #039;s disease
AbbVie (NYSE: ABBV) announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials - U-EXCEL, U-EXCEED and U-ENDURE - evaluating upadacitinib (RINVOQ®) in adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent. (Source: World Pharma News)
Source: World Pharma News - June 6, 2023 Category: Pharmaceuticals Tags: Featured AbbVie Business and Industry Source Type: news
Patient seeks to give back by participating in clinical trials to advance research
Mark Lewis is an advocate for participating in clinical trials. As a person who is immunocompromised and has been a Mayo Clinic patient for decades, he hopes to inspire others to join clinical trials for "the greater good." Lewis has lived with Crohn's disease, a type of inflammatory bowel disease (IBD) marked by inflammation of the lining of the digestive tract, since he was in high school in the mid-1970s. He's struggled with debilitating symptoms. Now, he's… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 2, 2023 Category: Databases & Libraries Source Type: news
Upadacitinib Superior to Placebo in Moderate-to-Severe Crohn Disease
WEDNESDAY, May 31, 2023 -- For patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 31, 2023 Category: Pharmaceuticals Source Type: news
AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients
Those who had had inflammatory bowel disease for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axial spondyloarthritis remission.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 25, 2023 Category: Gastroenterology Tags: Rheumatology News Source Type: news
A Close Look at the Data Backing Upadacitinib's Approval in Crohn's
(MedPage Today) -- The selective Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) improved clinical remission and endoscopic response rates compared with placebo in patients with moderate-to-severe Crohn's disease, according to two induction... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 25, 2023 Category: Gastroenterology Source Type: news
With Moderna windfall, Harvard professor and integrins legend Tim Springer donates $210M to his Institute for Protein Innovation
Tim Springer, with his name stapled to the likes of Moderna, Scholar Rock and Editas Medicine, plus the foundational work for Takeda’s ulcerative colitis and Crohn’s disease med Entyvio, has had a lot on his plate over the past five decades. In 2020, the Harvard professor became a billionaire…#timspringer #moderna #scholarrock #takeda #crohn #harvard #leukosite (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2023 Category: Consumer Health News Source Type: news
Warning: Prior Auth for Colonoscopy Is the Wrong Way to Go
(MedPage Today) -- Two weeks ago, I saw my 39-year-old patient with long-standing ulcerative colitis in clinic for new onset bleeding per rectum. She mentioned needing to attend an upcoming conference, and was eager to get to the source of the... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 24, 2023 Category: American Health Source Type: news
Mayo Clinic researchers link environmental exposures to liver disease
Mayo Clinic researchers have identified a diverse range of environmental chemicals in human bile in patients with primary sclerosing cholangitis, a rare, chronic liver disease of the bile ducts. The study, published in Exposome, represents a new frontier of research at Mayo Clinic's Center for Individualized Medicine that explores the exposome, the measure of environmental contributors to disease and health. Most people with primary sclerosing cholangitis also have some type of inflammatory bowel disease, such… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 23, 2023 Category: Databases & Libraries Source Type: news
Tofacitinib De-escalation in UC: Proceed With Caution Tofacitinib De-escalation in UC: Proceed With Caution
Patients with ulcerative colitis who de-escalate tofacitinib therapy may experience a disease flare, and not all will recapture clinical response with dose re-escalation, real-world data show.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 21, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
FDA Approves First Pill to Treat Moderate-to-Severe Crohn's
The FDA has approved the pill Rinvoq to treat moderate to severe Crohn's disease. (Source: WebMD Health)
Source: WebMD Health - May 19, 2023 Category: Consumer Health News Source Type: news
Scientists prevent signs of aging in zebrafish by targeting the gut
When it comes to slowing aging in humans, telomeres have long been a tempting target. These complex, repetitive sequences of DNA that cap the ends of chromosomes tick away the years by shortening each time a cell divides, eventually causing the cell to die.
The
jury’s still out
about whether reversing this shortening could be a molecular fountain of youth, but a new study in zebrafish is encouraging. When researchers lengthened telomeres in the gut cells of these tiny, translucent fish, they reversed signs of aging in the entire organism.
“It’s a really good paper,” says Ronald DePinho, a canc...
Source: ScienceNOW - May 19, 2023 Category: Science Source Type: news
FDA Approves First Pill to Treat Moderate-to-Severe Crohn's Disease
FRIDAY, May 19, 2023 -- Patients with Crohn ’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).
Rinvoq is meant to treat adults with moderately to severely active... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2023 Category: General Medicine Source Type: news
FDA Approves First Pill to Treat Moderate-to-Severe Crohn's Disease, Rinvoq (upadacitinib)
FRIDAY, May 19, 2023 -- Patients with Crohn’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).
Rinvoq is meant to treat adults with moderately to severely active... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2023 Category: General Medicine Source Type: news
U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of adults with moderately to severely... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 19, 2023 Category: Drugs & Pharmacology Source Type: news
